Judith Bell
Adult Health · Buffalo, NYNPI 1699107011
Payments from drug & device makers
Across 34 payments — averaging $106.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Phathom Pharmaceuticals, Inc.$712
- Alnylam Pharmaceuticals Inc.$272
- Neurocrine Biosciences, Inc.$251
- Teva Pharmaceuticals USA, Inc.$213
- Cvrx, Inc.$145
- plus $686 from 6 others
What the payments were for
- Food & beverage$3,607100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 12 | $1,329 |
| Phathom Pharmaceuticals, Inc. | 6 | $712 |
| Alnylam Pharmaceuticals Inc. | 2 | $272 |
| Neurocrine Biosciences, Inc. | 3 | $251 |
| Teva Pharmaceuticals USA, Inc. | 2 | $213 |
| Cvrx, Inc. | 1 | $145 |
| Acadia Pharmaceuticals Inc | 2 | $133 |
| Amgen | 1 | $125 |
| SK Life Science, Inc. | 2 | $125 |
| GSK | 1 | $121 |
| Urovant Sciences Inc | 1 | $111 |
| Otsuka America Pharmaceutical, Inc. | 1 | $71 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,607 in reported general payments places this provider in the 85th percentile of 3,828 adult health providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 227 | $125,221 |
| MyrbetriqMirabegron | 132 | $61,282 |
| OzempicSemaglutide | 23 | $26,803 |
| XareltoRivaroxaban | 18 | $10,159 |
| MovantikNaloxegol Oxalate | 50 | $9,942 |
| JardianceEmpagliflozin | 13 | $7,833 |
| Mirabegron ErMirabegron | 20 | $6,798 |
| LinzessLinaclotide | 11 | $6,094 |
| SantylCollagenase Clostridium Hist. | 15 | $4,708 |
| Potassium Chloride | 225 | $3,764 |
| Bumetanide | 192 | $3,706 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 21 | $3,301 |
| Levothyroxine Sodium | 323 | $3,283 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $3,131 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $2,890 |
Paid to pharmacies, not to this prescriber.
Other adult health in Buffalo
- Mary CiechoskiBuffalo$200K
- Rosemary HansenBuffalo$40K
- Susan DemarcoBuffalo$20K
- Marguerite CallahanNew York$1.4M
- Donna CatameroNew York$279K
- Kristen DurkinPort Jefferson Station$255K
- Katelyn McCormackAmherst$201K
- Patricia LorussoLancaster$161K
- Jennifer FioriniGlens Falls$151K
- Tia AlbroRochester$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.